Dextromethorphan Hydrobromide And Quinidine Sulfate Capsule
Product Images NDC 0480-2602

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Dextromethorphan Hydrobromide And Quinidine Sulfate (NDC 0480-2602). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

33159cef-figure-01 (Image 1)

Dextromethorphan hydrobromide and quinidine sulfate capsules in a white plastic bottle with a child-resistant cap. The label shows the proprietary name, dosage form (capsule), strengths (20 mg/10 mg), and route of administration (oral). The labeler is Teva Pharmaceuticals, Inc., and the product NDC number 0480-2602 is visible. The bottle contains 60 capsules.*

FDA Label Image

33159cef-figure-02 (Image 2)

Chemical structure of dextromethorphan hydrobromide monohydrate, the active ingredient in Dextromethorphan hydrobromide and quinidine sulfate capsules by Teva Pharmaceuticals, Inc.*

FDA Label Image

33159cef-figure-03 (Image 3)

Chemical structure diagram of dextromethorphan hydrobromide and quinidine sulfate, showing the molecular arrangement including a bicyclic system and functional groups, as well as a sulfate hydrate (H2SO4 · 2H2O) component.*

FDA Label Image

33159cef-figure-04 (Image 4)

A line graph comparing mean change from baseline in laughing and crying episodes over five visits between Dextromethorphan Hydrobromide and Quinidine Sulfate 20/10 mg and placebo groups. The graph shows significant reductions in episodes for the active drug group at multiple visits, indicated by asterisks, versus less change in the placebo group.*

FDA Label Image

33159cef-figure-05 (Image 5)

A line graph comparing the least square mean change from baseline CNS-LS score over five visits between two groups: one receiving Dextromethorphan hydrobromide and quinidine sulfate 20/10 mg, and a placebo group. The graph shows a greater decrease in CNS-LS score for the treatment group, with statistical significance indicated at visits 4 and 5 (Days 57 and 84).*

FDA Label Image

33159cef-figure-06 (Image 6)

Dextromethorphan hydrobromide and quinidine sulfate capsules with strengths 20 mg and 10 mg respectively, in an oral capsule dosage form. The label shows a clear amber capsule, produced by Teva Pharmaceuticals, Inc.*

FDA Label Image

Image 1 (Image 7)

Label for Dextromethorphan Hydrobromide and Quinidine Sulfate Capsules containing 20 mg/10 mg strength. The label indicates 60 capsules in the package, manufactured for Teva Pharmaceuticals, Inc., and includes storage and handling instructions. The NDC is 0480-2602-06.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.